DelveInsight’s, “ RNA Interference Pipeline Insight 2024 ” report provides comprehensive insights about 20+ companies and 90+ pipeline drugs in the RNA Interference pipeline landscape.

The global RNA interference (RNAi) market accounted for USD 1.23 billion in 2023 and is expected to reach USD 6.51 billion by 2034 with a CAGR of 16.33% during the forecast period 2024-2034.

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

AbbVie is staking hundreds of millions of dollars on RNA interference, agreeing on Wednesday to work with biotechnology startup ADARx Pharmaceuticals to develop experimental medicines for ...

More information: Matteo Iannacone et al, Targeting HBV with RNA interference: Paths to cure, Science Translational Medicine (2025). DOI: 10.1126/scitranslmed.adv3678 ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Amid headlines about rising cases of measles, falling vaccination rates and growing vaccine hesitancy, a quieter revolution is underway — one that could fundamentally reshape how we respond to global ...

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its ...

Article ‘Count’ and ‘Share’ for Laboratory of Viruses and RNA Interference based on listed parameters only. The articles listed below published by authors from Laboratory of Viruses and ...

Compared with placebo, researchers linked treatment with RNA interference therapeutics with significantly lower all-cause mortality (OR = 0.65; 95% CI, 0.45-0.83), longer 6-minute walk test ...